Analysts Offer Insights on Healthcare Companies: PDL BioPharma (PDLI) and Albireo Pharma Inc (ALBO)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDL BioPharma (PDLI) and Albireo Pharma Inc (ALBO).

PDL BioPharma (PDLI)

In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma, with a price target of $3. The company’s shares closed yesterday at $3.29.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.6% and a 49.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for PDL BioPharma.

See today’s analyst top recommended stocks >>

Albireo Pharma Inc (ALBO)

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Albireo Pharma Inc. The company’s shares closed yesterday at $34.20.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.5% and a 52.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Albireo Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $60.33, a 76.4% upside from current levels. In a report issued on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $62 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts